Assessing if a patient with DLBCL is responding to treatment using PET-CT and novel assays

Assessing if a patient with DLBCL is responding to treatment using PET-CT and novel assays

01:58 |

Related Videos

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma

5:11

iStopMM: the psychological effects of MGUS screening and changes to clinical presentation of myeloma

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

3:08

Welcome to the Video Journal of Hematology & Hematological Oncology 🎥🩸

The evolution of alloSCT in Richter's transformation and its combination with biological agents

4:48

The evolution of alloSCT in Richter's transformation and its combination with biological agents

The need for novel agents to treat patients with MCL who have relapsed after targeted therapy

2:22

The need for novel agents to treat patients with MCL who have relapsed after targeted therapy

A new classification for identifying high-risk myeloma based on cytogenetic abnormalities

2:14

A new classification for identifying high-risk myeloma based on cytogenetic abnormalities

Increasing diversity in myeloma clinical trials: addressing disparities & inclusion criteria

4:45

Increasing diversity in myeloma clinical trials: addressing disparities & inclusion criteria

Frontline treatment for CLL: the changing paradigm

1:31

Frontline treatment for CLL: the changing paradigm

The role of non-covalent BTKis in the era of covalent BTKis for B-cell malignancies

1:45

The role of non-covalent BTKis in the era of covalent BTKis for B-cell malignancies

The impact of biological sex in sickle cell disease

3:24

The impact of biological sex in sickle cell disease

The use of outpatient cilta-cel in the treatment of multiple myeloma

1:36

The use of outpatient cilta-cel in the treatment of multiple myeloma

Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics

1:14

Promising therapies under investigation in AL amyloidosis: anti-fibril agents & bispecifics

Personalizing the timing of SCT in patients with myelofibrosis

2:13

Personalizing the timing of SCT in patients with myelofibrosis

Moving away from chemoimmunotherapy and towards novel targeted agents in CLL

2:57

Moving away from chemoimmunotherapy and towards novel targeted agents in CLL

Insights into the diagnosis of smoldering myeloma from a UK perspective & ongoing trials

1:20

Insights into the diagnosis of smoldering myeloma from a UK perspective & ongoing trials

A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib

2:55

A model including CD49d expression to predict outcomes in patients with CLL treated with ibrutinib

Assessing if a patient with DLBCL is responding to treatment using PET-CT and novel assays

1:59

Assessing if a patient with DLBCL is responding to treatment using PET-CT and novel assays

The addition of venetoclax to hyper-CVAD-nelarabine and pegylated asparagine in T-ALL

2:19

The addition of venetoclax to hyper-CVAD-nelarabine and pegylated asparagine in T-ALL

Treatment-free remission after second-generation TKI treatment in CML

1:01

Treatment-free remission after second-generation TKI treatment in CML

Unanswered questions in MCL: when will we achieve cure?

1:32

Unanswered questions in MCL: when will we achieve cure?

Molecular MRD as a prognostic marker for AML patients with mutated CEBPA

1:13

Molecular MRD as a prognostic marker for AML patients with mutated CEBPA